AVROBIO, Inc. (AVRO)
| Market Cap | 39.65M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -109.08M |
| Shares Out | 43.77M |
| EPS (ttm) | -2.49 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 11,644 |
| Open | 0.910 |
| Previous Close | 0.910 |
| Day's Range | 0.891 - 0.919 |
| 52-Week Range | 0.560 - 1.980 |
| Beta | 1.69 |
| Analysts | Buy |
| Price Target | 3.57 (+300.49%) |
| Earnings Date | Mar 16, 2023 |
About AVRO
AVROBIO, Inc., a clinical-stage gene therapy company, develops ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose worldwide. Its gene therapies employ hematopoietic stem cells that are collected from patients and modified with a lentiviral vector to insert functional copies of the gene that is defective in the target disease. The company's product includes AVR-RD-01, a gene therapy for the treatment of Fabry disease. It is also developing AVR-RD-02, which is in phase 1/2 clinical trial for the treatment of ty... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 15 analysts, the average rating for AVRO stock is "Buy." The 12-month stock price forecast is $3.57, which is an increase of 300.49% from the latest price.
News
AVROBIO Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass.--(BUSINESS WIRE)--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company working to free people from a lifetime of genetic disease, today announced that the com...
AVROBIO Announces New Positive Clinical Data and Outlines Clinical Development Plan Following Regulatory Discussions for its Gaucher Disease Gene Therapy
CAMBRIDGE, Mass.--(BUSINESS WIRE)--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company working to free people from a lifetime of genetic disease, today announced new interim ...
AVROBIO to Share Comprehensive Gaucher Disease Program Update
CAMBRIDGE, Mass.--(BUSINESS WIRE)--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company working to free people from a lifetime of genetic disease, today announced that it will...
AVROBIO Reports Third Quarter 2022 Financial Results and Provides Business Update
CAMBRIDGE, Mass.
AVROBIO to Participate in the Sixth Annual Barclays Gene Editing/Therapy Summit
CAMBRIDGE, Mass.
AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass.
AVROBIO Receives Rare Pediatric Disease Designation from the U.S. FDA for First-in-Class Gene Therapy for Gaucher Disease
CAMBRIDGE, Mass.
AVROBIO Announces Completion of Patient Dosing in First Gene Therapy Clinical Trial for Cystinosis
CAMBRIDGE, Mass.
AVROBIO Granted ILAP Designation from U.K. MHRA for First-in-Class Gene Therapy for Gaucher Disease
CAMBRIDGE, Mass.
AVROBIO Reports Favorable Data on Use of Combined State-of-the-art In Vitro Cell-based Assays to Identify Potential Genotoxicity Risk of Integrating Vectors During Preclinical Development
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AVRO--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company working to free people from a lifetime of genetic disease, today reported favor...
AVROBIO to Present New Preclinical Data on Vector Safety at ESGCT Annual Congress
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AVRO--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company working to free people from a lifetime of genetic disease, today announced that...
AVROBIO Receives Rare Pediatric Disease Designation from U.S. Food and Drug Administration (FDA) for First Gene Therapy in Development for Cystinosis
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AVRO--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company working to free people from a lifetime of genetic disease, today announced that...
AVROBIO Announces Neuronopathic Mucopolysaccharidosis Type II (nMPS-II) or Hunter Syndrome Clinical Trial Application (CTA) Accepted by U.K. Regulatory Agency to Initiate Pediatric Phase 1/2 Gene Therapy Trial
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AVRO--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company working to free people from a lifetime of genetic disease, today announced that...
AVROBIO to Participate in Four Upcoming Investor Conferences in September
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AVRO--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company working to free people from a lifetime of genetic disease, today announced that...
AVROBIO Reports Second Quarter 2022 Financial Results and Provides Business Update
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AVRO--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company working to free people from a lifetime of genetic disease, today reported finan...
AVROBIO to Participate in Two Upcoming Investor Conferences in August
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AVRO--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a shared purpose to free people from a lifetime of genetic disease, today ...
AVROBIO Receives Orphan Drug Designation from the U.S. Food and Drug Administration for AVR-RD-05, a Gene Therapy for Mucopolysaccharidosis Type II (MPSII) or Hunter Syndrome
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AVRO--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a shared purpose to free people from a lifetime of genetic disease, today ...
AVROBIO (AVRO) Stock Up on Upbeat Data From Cystinosis Study
Results from AVROBIO's (AVRO) phase I/II study, which is evaluating its gene-therapy candidate for cystinosis, show the latter's potential to stabilize or reduce the impact of cystinosis on different ...
AVROBIO Announces Preclinical Gene Therapy Data for Pompe Disease at American Society of Gene and Cell Therapy (ASGCT) Annual Meeting
CAMBRIDGE, Mass.--(BUSINESS WIRE)--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a shared purpose to free people from a lifetime of genetic disease, today announced ...
AVROBIO Shares Jumps On Encouraging Data From Early-Stage Gene Therapy Study
AVROBIO Inc (NASDAQ: AVRO) reported new interim data from the Phase 1/2 gene therapy trial of AVR-RD-04 for cystinosis. Cystinosis is a condition characterized by the accumulation of the amino acid cy...
AVROBIO Reports Positive Data From Phase 1/2 Clinical Trial of Investigational Gene Therapy for Cystinosis, Including New Interim Data on Neurocognitive Measures
CAMBRIDGE, Mass.--(BUSINESS WIRE)--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a shared purpose to free people from a lifetime of genetic disease, today reported n...
AVROBIO to Present at the H.C. Wainwright Global Investment Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AVRO--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a shared purpose to free people from a lifetime of genetic disease, today ...
AVROBIO Reports First Quarter 2022 Financial Results and Provides Business Update
CAMBRIDGE, Mass.--(BUSINESS WIRE)--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a shared purpose to free people from a lifetime of genetic disease, today reported f...
AVROBIO to Present New Clinical and Preclinical Data at the ASGCT 25th Annual Meeting
CAMBRIDGE, Mass.--(BUSINESS WIRE)--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a shared purpose to free people from a lifetime of genetic disease, today announced ...
AVROBIO to Present at the 21st Annual Needham Virtual Healthcare Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a shared purpose to free people from a lifetime of genetic disease, today announced ...